Literature DB >> 8534425

Distribution of nicotinic subtypes in human brain.

J Court1, F Clementi.   

Abstract

The distribution of high-affinity nicotine and alpha-bungarotoxin receptors has been compared in a number of human brain areas and related to the available data on receptor subtype mRNA expression. Nicotine binding is high in the thalamus, striatum, and substantia nigra pars compacta, and although not generally high in the hippocampal formation, it is concentrated in the entorhinal cortex, the subicular complex, and the stratum lacunosum moleculare. Nicotine binding is relatively low in the cerebral cortex, but it demonstrates varied patterns of distribution in different areas. Nicotine binding is also present in the cerebellar cortex and dentate nucleus. Nicotine binding in the thalamus corresponds to alpha 3 expression, but at variance to data from rodents, there is little evidence of beta 2 mRNA in this brain area. By contrast, there is beta 2 mRNA but not alpha 3 mRNA in the striatum. In the hippocampal formation both alpha 3 and beta 2 mRNAs are expressed, but the pattern of distribution does not resemble nicotine binding, only reaching moderate levels in the dentate granule cell layer and in the CA3 region. In the neocortex, alpha 4 expression is more widely distributed than alpha 3, but both are associated with pyramidal neurons. The distribution of nicotine binding, concentrated in brain areas gating multimodal inputs and often uncorrelated with cholinergic innervation, suggests a neuromodulatory role, possibly facilitating glutamatergic transmission. The distribution of alpha-bungarotoxin binding is different from that of nicotine in the hippocampal formation, being highest in the CA1 region and the dentate granule cell layer, but similar to nicotine binding in the substantia nigra pars compacta.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534425     DOI: 10.1097/00002093-199501002-00003

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  15 in total

Review 1.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

Review 2.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

3.  Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice.

Authors:  R Paylor; M Nguyen; J N Crawley; J Patrick; A Beaudet; A Orr-Urtreger
Journal:  Learn Mem       Date:  1998 Sep-Oct       Impact factor: 2.460

4.  Lynx1 supports neuronal health in the mouse dorsal striatum during aging: an ultrastructural investigation.

Authors:  Atsuko Kobayashi; Rell L Parker; Ashley P Wright; Hajer Brahem; Pauline Ku; Katherine M Oliver; Andreas Walz; Henry A Lester; Julie M Miwa
Journal:  J Mol Neurosci       Date:  2014-07-17       Impact factor: 3.444

5.  The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Authors:  Sanna Janhunen; Paula Mielikäinen; Päivi Paldánius; Raimo K Tuominen; Liisa Ahtee; Seppo Kaakkola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

6.  A component of Premarin(®) enhances multiple cognitive functions and influences nicotinic receptor expression.

Authors:  Joshua S Talboom; Elizabeth B Engler-Chiurazzi; Paul Whiteaker; Alain R Simard; Ronald Lukas; Jazmin I Acosta; Laszlo Prokai; Heather A Bimonte-Nelson
Journal:  Horm Behav       Date:  2010-09-19       Impact factor: 3.587

Review 7.  The application of positron-emitting molecular imaging tracers in Alzheimer's disease.

Authors:  Robert M Cohen
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.488

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats.

Authors:  Britta Hahn; Mohammed Shoaib; Ian P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  2003-04-16       Impact factor: 4.530

Review 10.  Nicotinic receptors as CNS targets for Parkinson's disease.

Authors:  Maryka Quik; Tanuja Bordia; Kathryn O'Leary
Journal:  Biochem Pharmacol       Date:  2007-06-17       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.